Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | High-dose carfilzomib recaptures response in r/r multiple myeloma

Xiang Zhou • 11 Dec 2021
ASH 2021
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Lenalidomide

Xiang Zhou, MD, University Hospital of Würzburg, Würzburg, Germany, discusses results from a study investigating carfilzomib, a second-generation proteasome inhibitor, in patients with relapsed/refractory multiple myeloma. Dosage of carfilzomib depends on what regimen it is part of and the study attempted to elucidate if high-dose carfilzomib can capture response in patients resistant to low-dose carfilzomib. High-dose carfilzomib, defined as 36+ mg/m2, achieved a more robust progression-free survival in patients than low-dose carfilzomib. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals